Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...
Zacks.com on MSN22h
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock UpNovo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback